Ganglioside GM1 binds to the Trk protein and regulates receptor function.

A mutant cholera toxin B subunit that binds GM1- ganglioside but lacks immunomodulatory or toxic activity.

GM1-ganglioside receptor binding by the B subunit of cholera toxin (CtxB) is widely accepted to initiate toxin action by triggering uptake and delivery of the toxin A subunit into cells. More recently, GM1 binding by isolated CtxB, or the related B subunit of Escherichia coli heat-labile enterotoxin (EtxB), has been found to modulate leukocyte function, resulting in the down-regulation of proin...

GM1 ganglioside therapy in acute ischemic stroke.

Trial of ganglioside GM1 in acute stroke.

Ganglioside GM1 (100 mg) was given daily by intramuscular injection for 28 days in a double-blind placebo controlled trial of acute stroke. No significant difference was detected in a 6 month follow-up period between well matched control and active groups. Although the number of patients studied was small the findings are believed to indicate that GM1 is unlikely to be of value in the treatment...

GM1 ganglioside-independent intoxication by Cholera toxin

Cholera toxin (CT) enters and intoxicates host cells after binding cell surface receptors via its B subunit (CTB). We have recently shown that in addition to the previously described binding partner ganglioside GM1, CTB binds to fucosylated proteins. Using flow cytometric analysis of primary human jejunal epithelial cells and granulocytes, we now show that CTB binding correlates with expression...

GM1 ganglioside enhances synaptosomal resistance to chemically induced damage.

A neurotoxic agent, chlordecone, damages the limiting membrane of isolated synaptosomes prepared from rat brain. This is shown by increased levels of free, ionic calcium and increased permeability of synaptosomes, using the fluorimetric probe, fura-2. Pretreatment of synaptosomes with the monosialoganglioside GM1, attenuates the effect of chlordecone. A parallel preincubation of synaptosomes wi...